dc.contributor.authors |
Aziret, Mehmet; Subasi, Ozkan; Bilir, Cemil; Tozlu, Mukaddes; Altintoprak, Fatih; Karaman, Kerem; Ercan, Metin; Celebi, Fehmi |
|
dc.date.accessioned |
2022-12-20T13:24:44Z |
|
dc.date.available |
2022-12-20T13:24:44Z |
|
dc.date.issued |
2022 |
|
dc.identifier.issn |
0003-469X |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/98943 |
|
dc.description |
Bu yayının lisans anlaşması koşulları tam metin açık erişimine izin vermemektedir. |
|
dc.description.abstract |
BACKGROUND: In colorectal cancer (CRC), the mutation of the K(N)RAS gene has a significant impact on the clinical course, and is associated with a negative prognosis. We aim to present the morbidity and long-term results in patients with wild/mut-K(N)RAS, undergoing CRC surgery. METHODS: A total of 116 patients who underwent surgery for colorectal cancers with wild/mut-K(N)RAS were included in this retrospective study. The patients were divided into two groups: wild-K(N)RAS patients (Group 1) and mutant- K(N)RAS patients (Group 2). Results were evaluated for clinical, operative, morbidity and long-term survival outcomes. MATERIALS AND METHODS: The highest surgical site infection (SSI) rate (OR=140.339)(4.303-4581.307)(P=0.005) was seen in patients given Bevacizumab during neoadjuvant treatment. Meanwhile, the SSI site infection rate was at its lowest in cases where minimally invasive surgery was preferred (OR=0.062)(0.006-0.628)(P=0.019). In addition, the overall median survival rate for the total cohort was 38 +/- 3.1 (31-44) months. Multivariate analysis showed that CEA (>5ng/mL)(HR 2.94)(1.337-6.492))(P=0.007); tumor stage (P=0.034), T(T4) stage (HR 1.91)(1.605-252.6)(P=0.02); metastasectomy/ablation (HR 0.19)(0.077-0.520)(P=0.001); the number of removed metastatic lymph nodes (HR 1.08)(1.010-1.155)(P=0.025); tumor implant or nodule (HR 2.71)(1.102-6.706)(P=0.03); curative resection (HR 2.40)(0.878-6.580)(P=0.042) to be factors affecting the overall survival rate. CONCLUSION: Treatment with Bevacizumab during the neoadjuvant period in mut-K(N)RAS cases, surgical technique and complications of Grade 3 or higher are risk factors for SSI on morbidity in patients with mut/wild-K(N)RAS undergoing colorectal cancer surgery. Moreover, CEA (>5ng/mL), tumor stage, T stage, metastasectomy/ablation, the number of removed metastatic lymph nodes, tumor implant/nodule and curative resection are risk factors on the overall survival rate. |
|
dc.language |
English |
|
dc.language.iso |
eng |
|
dc.subject |
Surgery |
|
dc.subject |
Bevacizumab |
|
dc.subject |
Colorectal cancer |
|
dc.subject |
K(N)RAS mutation |
|
dc.subject |
Morbidity |
|
dc.subject |
Mortality |
|
dc.title |
Morbidity and long-term results in patients with wild and mutant type Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations undergoing colorectal cancer surgery |
|
dc.identifier.volume |
93 |
|
dc.identifier.startpage |
65 |
|
dc.identifier.endpage |
77 |
|
dc.relation.journal |
ANNALI ITALIANI DI CHIRURGIA |
|
dc.identifier.issue |
1 |
|
dc.identifier.eissn |
2239-253X |
|
dc.contributor.author |
Aziret, Mehmet |
|
dc.contributor.author |
Subasi, Ozkan |
|
dc.contributor.author |
Bilir, Cemil |
|
dc.contributor.author |
Tozlu, Mukaddes |
|
dc.contributor.author |
Altintoprak, Fatih |
|
dc.contributor.author |
Karaman, Kerem |
|
dc.contributor.author |
Ercan, Metin |
|
dc.contributor.author |
Celebi, Fehmi |
|
dc.relation.publicationcategory |
Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı |
|